An Exploratory Phase 2, 2-part, Randomized, Double blind, Placebo controlled Study With a Long term, Open label Period to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del
Phase of Trial: Phase II
Latest Information Update: 14 Jan 2019
At a glance
- Drugs Ivacaftor/lumacaftor (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- Sponsors Vertex Pharmaceuticals
- 16 Aug 2018 Status changed from not yet recruiting to recruiting.
- 06 Jul 2018 Status changed from not stated to recruiting.
- 15 Jun 2018 New trial record